241 related articles for article (PubMed ID: 34337865)
1. Modular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug Delivery.
van der Meel R; Chen S; Zaifman J; Kulkarni JA; Zhang XRS; Tam YK; Bally MB; Schiffelers RM; Ciufolini MA; Cullis PR; Tam YYC
Small; 2021 Sep; 17(37):e2103025. PubMed ID: 34337865
[TBL] [Abstract][Full Text] [Related]
2. Micro-syringe chip-guided intratumoral administration of lipid nanoparticles for targeted anticancer therapy.
Kim J; Song S; Gwak M; Cho H; Yun WS; Hwang N; Kim J; Lee JS; Kim DH; Kim H; Jeon SI; Kim TI; Kim K
Biomater Res; 2023 Oct; 27(1):102. PubMed ID: 37845762
[TBL] [Abstract][Full Text] [Related]
3. Development of amino acid-modified biodegradable lipid nanoparticles for siRNA delivery.
Patel P; Fetse J; Lin CY; Guo Y; Hasan MR; Nakhjiri M; Zhao Z; Jain A; Cheng K
Acta Biomater; 2022 Dec; 154():374-384. PubMed ID: 36191773
[TBL] [Abstract][Full Text] [Related]
4. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
[TBL] [Abstract][Full Text] [Related]
5. Chemistry of Lipid Nanoparticles for RNA Delivery.
Eygeris Y; Gupta M; Kim J; Sahay G
Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
[TBL] [Abstract][Full Text] [Related]
6. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
[TBL] [Abstract][Full Text] [Related]
7. A lipid nanoparticle platform for mRNA delivery through repurposing of cationic amphiphilic drugs.
Bogaert B; Sauvage F; Guagliardo R; Muntean C; Nguyen VP; Pottie E; Wels M; Minnaert AK; De Rycke R; Yang Q; Peer D; Sanders N; Remaut K; Paulus YM; Stove C; De Smedt SC; Raemdonck K
J Control Release; 2022 Oct; 350():256-270. PubMed ID: 35963467
[TBL] [Abstract][Full Text] [Related]
8. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics.
Gindy ME; Feuston B; Glass A; Arrington L; Haas RM; Schariter J; Stirdivant SM
Mol Pharm; 2014 Nov; 11(11):4143-53. PubMed ID: 25317715
[TBL] [Abstract][Full Text] [Related]
9. Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells.
Khare P; Dave KM; Kamte YS; Manoharan MA; O'Donnell LA; Manickam DS
AAPS J; 2021 Dec; 24(1):8. PubMed ID: 34873640
[TBL] [Abstract][Full Text] [Related]
10. Structure, activity and uptake mechanism of siRNA-lipid nanoparticles with an asymmetric ionizable lipid.
Suzuki Y; Ishihara H
Int J Pharm; 2016 Aug; 510(1):350-8. PubMed ID: 27374199
[TBL] [Abstract][Full Text] [Related]
11. PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM production.
Suzuki T; Suzuki Y; Hihara T; Kubara K; Kondo K; Hyodo K; Yamazaki K; Ishida T; Ishihara H
Int J Pharm; 2020 Oct; 588():119792. PubMed ID: 32827675
[TBL] [Abstract][Full Text] [Related]
12. Elucidation of the physicochemical properties and potency of siRNA-loaded small-sized lipid nanoparticles for siRNA delivery.
Sato Y; Note Y; Maeki M; Kaji N; Baba Y; Tokeshi M; Harashima H
J Control Release; 2016 May; 229():48-57. PubMed ID: 26995758
[TBL] [Abstract][Full Text] [Related]
13. Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.
Xu Y; Ou M; Keough E; Roberts J; Koeplinger K; Lyman M; Fauty S; Carlini E; Stern M; Zhang R; Yeh S; Mahan E; Wang Y; Slaughter D; Gindy M; Raab C; Thompson C; Hochman J
Mol Pharm; 2014 May; 11(5):1424-34. PubMed ID: 24588618
[TBL] [Abstract][Full Text] [Related]
14. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.
Basha G; Novobrantseva TI; Rosin N; Tam YY; Hafez IM; Wong MK; Sugo T; Ruda VM; Qin J; Klebanov B; Ciufolini M; Akinc A; Tam YK; Hope MJ; Cullis PR
Mol Ther; 2011 Dec; 19(12):2186-200. PubMed ID: 21971424
[TBL] [Abstract][Full Text] [Related]
15. Stimuli-Responsive Polymer-Prodrug Hybrid Nanoplatform for Multistage siRNA Delivery and Combination Cancer Therapy.
Saw PE; Yao H; Lin C; Tao W; Farokhzad OC; Xu X
Nano Lett; 2019 Sep; 19(9):5967-5974. PubMed ID: 31381852
[TBL] [Abstract][Full Text] [Related]
16. Dexamethasone prodrugs as potent suppressors of the immunostimulatory effects of lipid nanoparticle formulations of nucleic acids.
Chen S; Zaifman J; Kulkarni JA; Zhigaltsev IV; Tam YK; Ciufolini MA; Tam YYC; Cullis PR
J Control Release; 2018 Sep; 286():46-54. PubMed ID: 30026080
[TBL] [Abstract][Full Text] [Related]
17. Polydispersity characterization of lipid nanoparticles for siRNA delivery using multiple detection size-exclusion chromatography.
Zhang J; Haas RM; Leone AM
Anal Chem; 2012 Jul; 84(14):6088-96. PubMed ID: 22816783
[TBL] [Abstract][Full Text] [Related]
18. Development of a Microfluidic-Based Post-Treatment Process for Size-Controlled Lipid Nanoparticles and Application to siRNA Delivery.
Kimura N; Maeki M; Sato Y; Ishida A; Tani H; Harashima H; Tokeshi M
ACS Appl Mater Interfaces; 2020 Jul; 12(30):34011-34020. PubMed ID: 32667806
[TBL] [Abstract][Full Text] [Related]
19. Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting.
Sakurai Y; Mizumura W; Murata M; Hada T; Yamamoto S; Ito K; Iwasaki K; Katoh T; Goto Y; Takagi A; Kohara M; Suga H; Harashima H
Mol Pharm; 2017 Oct; 14(10):3290-3298. PubMed ID: 28789523
[TBL] [Abstract][Full Text] [Related]
20. The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy.
Francia V; Schiffelers RM; Cullis PR; Witzigmann D
Bioconjug Chem; 2020 Sep; 31(9):2046-2059. PubMed ID: 32786370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
